Reasonableness of developing a new antifungal product in the form of ear drops antineoplastic agents, available on pharmaceutical market of the Republic of Moldova

Abstract

Introduction: There has been an increase in the prevalence of otomycosis in recent years.The most recommended and dominate treatment of otomycosis, is topical instillation of ear drops. Ear drops provide the advantages of combination therapy, extending the range of therapeutic options.Considering poly-etiology of this disease (the possible presence of fungal bacterial flora), treatment should include antimicrobial, antifungal, antiinflammatory, and if necessary, an analgesic effect that is achieved by the use of combined ear drops. Purpose and objectives: analyze the available pharmaceutical products used for treatment of otomycosis. The rational application of these medications makes it possible to eliminate rapidly a variety of etiological factors, reduce the severity of inflammation, and to improve the quality of patient's life. Materials and methods: Forresearch it was used State Nomenclature of drugs of Republic of Moldova (01.03.2014); Nomenclature of drugs of Romania (01.03.2014); State Register of drugs of Russia (01.03.2014); Formulation of European Medical Agency (01.03.2014); Formulation of USA (FDA Drugs) (20.02.2014); Great Britain Formulation (01.02.2014); instructions for use of drugs; Standards of quality of analytical documents and therapeutic protocols in otorhinolaryngology (section "ear diseases"). Results: Combined eardrops were analyzed in terms of their presence in the pharmaceutical market of RM in comparing with Russia, EU countries, USA and Canada. Nomenclatures of drugs from 7 countries (Moldova, Romania, Russia, Britain, France, USA and Canada) were examined. The results indicate that most frequently used 43 names of combined ear drops produced by 38 companies from 15 countries. Of these 38 companies only 2 produce combined ear drops which contains antifungal component.The pharmaceutical market in RM has 13 names of ear drops. The most products (58.3%) are combinations of antimicrobial v, corticosteroids, antiinflammatory, anesthetic and antiseptic medicines. Unfortunately, there are notregistered combined ear drops that contain antifungal component. Conclusions: In conclusion it is important to develop a new composition of ear drops, containing antibacterial and antifungal components.